Abstract
Cefiderocol is a siderophore cephalosporin designed mainly for treatment of infections caused by b-lactam and multidrug-resistant Gram-negative bacteria. Burkholderia pseudomallei clinical isolates are usually highly cefiderocol susceptible, with in vitro resistance found in a few isolates. Resistance in clinical B. pseudomallei isolates from Australia is caused by a hitherto uncharacterized mechanism. We show that, like in other Gram-negatives, the PiuA outer membrane receptor plays a major role in cefiderocol nonsusceptibility in isolates from Malaysia.
| Original language | English |
|---|---|
| Pages (from-to) | e00171-23 |
| Number of pages | 1 |
| Journal | Antimicrobial Agents and Chemotherapy |
| Volume | 67 |
| Issue number | 6 |
| Early online date | 3 May 2023 |
| DOIs | |
| Publication status | Published - Jun 2023 |
Bibliographical note
Funding Information:This work was funded in part by an award from Shionogi, Inc., NAU start-up funds, and grant HDTRA1-17-10051 from the United States Defense Threat Reduction Agency (DTRA). The contents are solely the responsibility of the authors and do not necessarily represent the official views of DTRA or the Department of Defense. The sponsors had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. We thank Vanessa Rigas at Menzies School of Health Research for expertise in B. pseudomallei identification and laboratory support.
Publisher Copyright:
Copyright © 2023 Hall et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.